Enzalutamid bei kastrationsresistentem Prostatakarzinom
- PMID: 32018325
- DOI: 10.1055/a-0962-6453
Enzalutamid bei kastrationsresistentem Prostatakarzinom
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Comment on
-
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources